The European Patent Office (EPO) has revealed in its annual report for 2016 that European patent filings in pharmaceuticals decreased by 5%.

The report also showed that European patent filings in biotechnology increased by 0.3% last year.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In the UK, the pharmaceutical-related patent applications filed at the rose 20.9% in biotechnology and 3.7% in pharmaceuticals.

A total of 5,744 biotechnology-related patent applications and 5,754 pharmaceutical-related patent applications were filed with the EPO last year compared to 2015, when there were 5,724 and 6,055 respectively.

Intellectual property firm Marks & Clerk patent attorney and partner Dr Paul Chapman said: “Despite the small decrease in biotechnology and pharmaceutical European patent filings from around the world, there was in fact an increase in filings coming from the UK, with a significant increase in the biotechnology field.

See Also:

"Although the leading filers in biotechnology and pharmaceuticals may currently be found in mainland Europe, the figures suggest that UK-based filers may be catching up."

“Although the leading filers in biotechnology and pharmaceuticals may currently be found in mainland Europe, the figures suggest that UK-based filers may be catching up.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The challenges Brexit will likely provide for UK-based companies are well known, but hopefully it will also offer opportunities.

"The biotechnology and pharmaceutical sectors are reliant on a strong IP system. Filing patents through the European Patent Office and utilising the current European Patent Convention system will not change post-Brexit.”

Biotechnology and pharmaceuticals were ranked the tenth and ninth strongest sector, respectively, for European patent applications worldwide.

The Institut national de la santé et de la recherche médicale (INSERM), Novartis and Merck were the leading filers of European patents in pharmaceutical technology, while Hoffman-La Roche, Inserm and Novozymes were the leading filers of European patents in biotechnology.